Onconetix, Inc. (ONCO) stock
ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.21+0.18 (+5.94%)
Close on Nov 13, 2026Market cap $12.68MP/E –Yield –
Onconetix EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Onconetix's EPS for the twelve months ending Sep 30, 2024 was -$8128.03. For fiscal 2025 it was -$16.56. The highest annual figure on record is -$16.56 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.56 | – |
| FY2024 | Dec 31, 2024 | -$1823.39 | – |
| FY2023 | Dec 31, 2023 | -$7433.25 | – |
| FY2022 | Dec 31, 2022 | -$3740.00 | – |
| FY2021 | Dec 31, 2021 | -$4284.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.28 | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.71 | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.25 | – |
| Q2 FY2025 | Jun 30, 2025 | -$237.91 | – |
| Q1 FY2025 | Mar 31, 2025 | -$227.25 | – |
| Q3 FY2024 | Sep 30, 2024 | -$249.08 | – |
| Q2 FY2024 | Jun 30, 2024 | -$2191.59 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1706.80 | – |
| Q4 FY2023 | Dec 31, 2023 | -$3980.56 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1037.85 | – |
| Q4 FY2022 | Dec 31, 2022 | -$673.77 | – |
| Q3 FY2022 | Sep 30, 2022 | -$918.00 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1224.00 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1156.00 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1453.26 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1360.00 | – |
| Q2 FY2021 | Jun 30, 2021 | -$986.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?